ArticleFrontiers in pharmacology2026
Survival outcomes, determinants, and hemodynamic trajectories with intravenous β
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis and septic shock impose severe cardiovascular stress characterized by sympathetic overactivation and detrimental tachycardia, which is strongly linked to poor outcomes. While ultra-short-acting β Objective: To compare survival and hemodynamic trajectories associated with two intravenous β Methods: In this retrospective cohort study, we examined the MIMIC-IV database for vasopressor-dependent patients with septic shock and incident tachyarrhythmia. Employing propensity score matching and restricted cubic splines analysis, we compared the mortality of intravenous esmolol and metoprolol in septic shock patients with tachyarrhythmia. Results: The primary outcome was 28-day ICU mortality; the secondary outcomes were longitudinal hemodynamic indices (heart rate, blood pressure, lactate). Overall, 31.82% (1,494/4,695) cases died by day 28. Metoprolol was used in 44.6% and esmolol in 1.9%. In multivariable Cox models with spline-informed covariate handling, both esmolol and metoprolol were associated with lower 28-day mortality versus no β Conclusion: In real-world septic shock with arrhythmia, intravenous β
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.